JOP20210249A1 - مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv - Google Patents
مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbvInfo
- Publication number
- JOP20210249A1 JOP20210249A1 JOP/2021/0249A JOP20210249A JOP20210249A1 JO P20210249 A1 JOP20210249 A1 JO P20210249A1 JO P20210249 A JOP20210249 A JO P20210249A JO P20210249 A1 JOP20210249 A1 JO P20210249A1
- Authority
- JO
- Jordan
- Prior art keywords
- hbv
- treatment
- fused ring
- induced diseases
- pyrimidone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
يتعلق الاختراع الحالي بمركبات وفقا للصيغة (I)، وتركيبات صيدلية تتضمن واحد على الأقل من المركبات المذكورة، واستخدامها كعلاج، واستخدامها في معالجة عدوى فيروس التهاب الكبد الوبائى B (HBV) المزمن. يتعلق الاختراع الحالي أيضا بطرق تحضير مركبات وفقا للصيغة (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19162954 | 2019-03-14 | ||
PCT/EP2020/056884 WO2020182990A1 (en) | 2019-03-14 | 2020-03-13 | Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210249A1 true JOP20210249A1 (ar) | 2023-01-30 |
Family
ID=65817822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0249A JOP20210249A1 (ar) | 2019-03-14 | 2020-03-13 | مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv |
Country Status (23)
Country | Link |
---|---|
US (1) | US20230091047A1 (ar) |
EP (1) | EP3938362A1 (ar) |
JP (1) | JP2022524456A (ar) |
KR (1) | KR20210139319A (ar) |
CN (1) | CN113710667A (ar) |
AR (1) | AR118358A1 (ar) |
AU (1) | AU2020235270A1 (ar) |
BR (1) | BR112021017415A2 (ar) |
CA (1) | CA3132531A1 (ar) |
CL (1) | CL2021002390A1 (ar) |
CO (1) | CO2021011295A2 (ar) |
CR (1) | CR20210482A (ar) |
DO (1) | DOP2021000185A (ar) |
EA (1) | EA202192512A1 (ar) |
EC (1) | ECSP21067189A (ar) |
IL (1) | IL286210A (ar) |
JO (1) | JOP20210249A1 (ar) |
MA (1) | MA55286A (ar) |
MX (1) | MX2021011107A (ar) |
PE (1) | PE20212325A1 (ar) |
SG (1) | SG11202109575UA (ar) |
TW (1) | TW202100524A (ar) |
WO (1) | WO2020182990A1 (ar) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202227435A (zh) * | 2020-09-11 | 2022-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療hbv感染或hbv誘發的疾病之稠合環嘧啶酮衍生物 |
KR20230091929A (ko) * | 2020-10-21 | 2023-06-23 | 알리고스 테라퓨틱스 인코포레이티드 | 바이사이클릭 화합물 |
US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
WO2023205653A1 (en) * | 2022-04-20 | 2023-10-26 | Aligos Therapeutics, Inc. | Bicyclic compounds |
US20230374008A1 (en) * | 2022-04-20 | 2023-11-23 | Aligos Therapeutics, Inc. | Bicyclic compounds |
WO2024015425A1 (en) | 2022-07-14 | 2024-01-18 | Fmc Corporation | Herbicidal benzoxazines |
WO2024073559A1 (en) * | 2022-09-30 | 2024-04-04 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2078719A4 (en) * | 2006-09-28 | 2009-11-11 | Dainippon Sumitomo Pharma Co | COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION |
US20100190687A1 (en) * | 2007-04-20 | 2010-07-29 | Boyle Craig D | Pyrimidinone derivatives and methods of use thereof |
CN101854597B (zh) | 2009-04-03 | 2015-06-03 | 中兴通讯股份有限公司 | 大消息模式融合ip消息传输方法及系统 |
WO2011111880A1 (ko) * | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
JP2012126698A (ja) * | 2010-12-17 | 2012-07-05 | Tsutomu Takeuchi | テトラヒドロピリドピリミジン誘導体を有効成分とするbaffの結合阻害剤 |
CA2972434A1 (en) * | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
WO2018083081A1 (en) * | 2016-11-03 | 2018-05-11 | F. Hoffmann-La Roche Ag | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
-
2020
- 2020-03-13 CN CN202080020919.0A patent/CN113710667A/zh active Pending
- 2020-03-13 PE PE2021001481A patent/PE20212325A1/es unknown
- 2020-03-13 BR BR112021017415A patent/BR112021017415A2/pt unknown
- 2020-03-13 CR CR20210482A patent/CR20210482A/es unknown
- 2020-03-13 SG SG11202109575UA patent/SG11202109575UA/en unknown
- 2020-03-13 MA MA055286A patent/MA55286A/fr unknown
- 2020-03-13 KR KR1020217032292A patent/KR20210139319A/ko unknown
- 2020-03-13 JO JOP/2021/0249A patent/JOP20210249A1/ar unknown
- 2020-03-13 EA EA202192512A patent/EA202192512A1/ru unknown
- 2020-03-13 MX MX2021011107A patent/MX2021011107A/es unknown
- 2020-03-13 US US17/438,767 patent/US20230091047A1/en active Pending
- 2020-03-13 TW TW109108504A patent/TW202100524A/zh unknown
- 2020-03-13 WO PCT/EP2020/056884 patent/WO2020182990A1/en active Application Filing
- 2020-03-13 AU AU2020235270A patent/AU2020235270A1/en not_active Abandoned
- 2020-03-13 AR ARP200100713A patent/AR118358A1/es unknown
- 2020-03-13 EP EP20710938.0A patent/EP3938362A1/en active Pending
- 2020-03-13 CA CA3132531A patent/CA3132531A1/en active Pending
- 2020-03-13 JP JP2021554985A patent/JP2022524456A/ja not_active Withdrawn
-
2021
- 2021-08-26 CO CONC2021/0011295A patent/CO2021011295A2/es unknown
- 2021-09-09 IL IL286210A patent/IL286210A/en unknown
- 2021-09-09 DO DO2021000185A patent/DOP2021000185A/es unknown
- 2021-09-10 EC ECSENADI202167189A patent/ECSP21067189A/es unknown
- 2021-09-13 CL CL2021002390A patent/CL2021002390A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230091047A1 (en) | 2023-03-23 |
CO2021011295A2 (es) | 2021-09-20 |
JP2022524456A (ja) | 2022-05-02 |
CN113710667A (zh) | 2021-11-26 |
TW202100524A (zh) | 2021-01-01 |
ECSP21067189A (es) | 2021-11-18 |
MX2021011107A (es) | 2022-01-19 |
KR20210139319A (ko) | 2021-11-22 |
AR118358A1 (es) | 2021-09-29 |
DOP2021000185A (es) | 2022-01-16 |
AU2020235270A1 (en) | 2021-08-12 |
SG11202109575UA (en) | 2021-09-29 |
PE20212325A1 (es) | 2021-12-14 |
CA3132531A1 (en) | 2020-09-17 |
EP3938362A1 (en) | 2022-01-19 |
BR112021017415A2 (pt) | 2022-02-01 |
IL286210A (en) | 2021-10-31 |
EA202192512A1 (ru) | 2022-02-16 |
WO2020182990A1 (en) | 2020-09-17 |
CR20210482A (es) | 2021-11-09 |
CL2021002390A1 (es) | 2022-04-22 |
MA55286A (fr) | 2022-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210249A1 (ar) | مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv | |
PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
PH12018550201A1 (en) | Hepatitis b antiviral agents | |
PH12018550148A1 (en) | Hepatitis b antiviral agents | |
ZA202107015B (en) | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | |
PH12021551116A1 (en) | Functionalized heterocycles as antiviral agents | |
MX2017007814A (es) | Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. | |
PH12020550065A1 (en) | Hepatitis b antiviral agents | |
MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
PH12019550113A1 (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
PH12015501560A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
MX2021003253A (es) | Heterociclos funcionalizados como agentes antivirales. | |
MX2021004593A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
PH12021550632A1 (en) | Monomer and multimeric anti-hbv agents | |
MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
MX2022009871A (es) | Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih). | |
IN2011CH03893A (ar) | ||
MX2021013594A (es) | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. | |
MX2021014576A (es) | Derivados heterociclicos condensados como agentes antivirales. | |
EA201892732A1 (ru) | Противовирусные средства для лечения гепатита в | |
MX2019011173A (es) | Compuesto que contiene silicio para la resistencia a la infeccion por el virus de la hepatitis c. | |
MX2019015480A (es) | Preparacion medicinal combinada para tratar infecciones virales. | |
EA202092107A1 (ru) | Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
GR1008805B (el) | Στερεο φαρμακευτικο σκευασμα περιεχον χαμηλη δοση εντεκαβιρης και μεθοδος παρασκευης αυτου |